Lexaria Bioscience Corp. is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. Cannabinoids are poorly absorbed by the body’s gastrointestinal tract and consumers often default to alternate routes of administration like smoking to achieve higher effectiveness. The Company’s lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also
masking taste.
The Company’s technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids.
Additionally, patents are pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
19